![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. 1-bp, Propane
2. N-propylbromide
3. Propyl Bromide
1. 106-94-5
2. N-propyl Bromide
3. Propyl Bromide
4. Propane, 1-bromo-
5. Propane, Bromo-
6. 1-bromo-propane
7. 1-propyl Bromide
8. Propylbromide
9. Mfcd00000254
10. Dtxsid6021874
11. Chebi:47105
12. Y9746dne68
13. 1-bromopropane-d7
14. Bromopropane
15. N-propylbromide
16. Ccris 30
17. Bromopropane, 1-
18. 40422-05-7
19. Hsdb 1068
20. Einecs 203-445-0
21. Bromo-propane
22. Unii-y9746dne68
23. 1-propylbromide
24. 1-bp
25. 3-bromopropane
26. Ai3-18129
27. 1-brompropane
28. 26446-77-5
29. 1-bromo Propane
30. 3-bromo Propane
31. Prbr
32. 1-bromanylpropane
33. N-prbr
34. 1-bromopropane, 99%
35. N-c3h7br
36. Ec 203-445-0
37. Schembl2478
38. Propyl Bromide [mi]
39. 1-bromopropane [hsdb]
40. 1-bromopropane [iarc]
41. Dtxcid401874
42. Schembl6999850
43. Chembl1230095
44. 1-bromopropane, Analytical Standard
45. Tox21_200619
46. Br1117
47. Stl264215
48. Akos000118833
49. Ncgc00091561-01
50. Ncgc00091561-02
51. Ncgc00258173-01
52. 3br
53. Cas-106-94-5
54. Ls-12961
55. B0638
56. Ft-0607548
57. Ft-0656570
58. En300-19391
59. Inchi=1/c3h7br/c1-2-3-4/h2-3h2,1h
60. A801541
61. Q161589
62. J-504471
63. F0001-0130
Molecular Weight | 122.99 g/mol |
---|---|
Molecular Formula | C3H7Br |
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 0 |
Rotatable Bond Count | 1 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 0 |
Heavy Atom Count | 4 |
Formal Charge | 0 |
Complexity | 7.2 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
... In this study, the factors influencing the disposition and biotransformation of 1-bromopropane (1-BrP) were examined in male F344 rats and B6C3F1 mice following inhalation exposure (800 ppm) or intravenous administration (5, 20, and 100 mg/kg). (1,2,3-(13)C)1-BrP and (1-(14)C)1-BrP were administered to enable characterization of urinary metabolites using NMR spectroscopy, LC-MS/MS, and HPLC coupled radiochromatography. Exhaled breath volatile organic chemicals (VOC), exhaled CO(2), urine, feces, and tissues were collected for up to 48 h post-administration for determination of radioactivity distribution. Rats and mice exhaled a majority of the administered dose as either VOC (40-72%) or (14)CO(2) (10-30%). For rats, but not mice, the percentage of the dose exhaled as VOC increased between the mid ( approximately 50%) and high ( approximately 71%) dose groups; while the percentage of the dose exhaled as (14)CO(2) decreased (19 to 10%). The molar ratio of exhaled (14)CO(2) to total released bromide, which decreased as dose increased, demonstrated that the proportion of 1-BrP metabolized via oxidation relative to pathways dependent on glutathione conjugation is inversely proportional to dose in the rat. ((14)C)1-BrP equivalents were recovered in urine (13-17%, rats; 14-23% mice), feces (<2%), or retained in the tissues and carcass (<6%) of rats and mice administered i.v. 5 to 100 mg/kg ((14)C)1-BrP. ... Rats pretreated with 1-aminobenzotriazole (ABT), a potent inhibitor of P450 excreted less in urine (down 30%), exhaled as (14)CO2 (down 80%), or retained in liver (down 90%), with a concomitant increase in radioactivity expired as VOC (up 52%). Following ABT pretreatment, rat urinary metabolites were reduced in number from 10 to 1, N-acetyl-S-propylcysteine, which accounted for >90% of the total urinary radioactivity in ABT pretreated rats. Together, these data demonstrate a role for cytochrome P450 and glutathione in the dose-dependent metabolism and disposition of 1-BrP in the rat.
PMID:16513153 Garner CE et al; Toxicol Appl Pharmacol 215 (1): 23-36 (2006)
.../It is/ reported that orally administered 1-bromopropane is excreted in expired air.
Bingham, E.; Cohrssen, B.; Powell, C.H.; Patty's Toxicology Volumes 1-9 5th ed. John Wiley & Sons. New York, N.Y. (2001)., p. V5 190
Parent compound and metabolites are excreted in urine as mercapturic acids.
Jones AR et al; Xenobiotica 9 (12): 763 (1980)
/Investigators/ injected Sprague-Dawley rats intraperitoneally with 200 mg/kg 1-BP and observed a rapid excretion of greater than half of the administered dose in expired air. By hour 100, 25% of the 1-BP dose was excreted in the urine.
American Conference of Governmental Industrial Hygienists. Documentation of the TLVs and BEIs with Other World Wide Occupational Exposure Values. 7th Ed. CD-ROM Cincinnati, OH 45240-1634 2013.
For more Absorption, Distribution and Excretion (Complete) data for 1-Bromopropane (7 total), please visit the HSDB record page.
... Six workers, 1 male and 5 female, were exposed to high ambient 1-Bromopropane (1-BP) concentrations while employed in a golf club cleaning factory. 1-BP was identified in the bulk solvent sample used by the workers and confirmed the workers' daily occupational exposure to 1-BP for 3-10 months. The major presenting symptoms were tingling pain, soreness in lower extremities, and paresthesia. N-acetyl-S-(n-propyl)-L-cysteine (AcPrCys), a 1-BP metabolite, was identified by LC/MS/MS in the urine (0.171-1.74 mg/g-Cr) of these workers 5-26 days following 1-BP exposure. ...
PMID:26161839 Wang TH et al; Clin Toxicol (Phila) 53 (8): 823-6 (2015)
... In this study, the factors influencing the disposition and biotransformation of 1-bromopropane (1-BrP) were examined in male F344 rats and B6C3F1 mice following inhalation exposure (800 ppm) or intravenous administration (5, 20, and 100 mg/kg). (1,2,3-(13)C)1-BrP and (1-(14)C)1-BrP were administered to enable characterization of urinary metabolites using NMR spectroscopy, LC-MS/MS, and HPLC coupled radiochromatography. ... Metabolites characterized in urine of rats and mice include N-acetyl-S-propylcysteine, N-acetyl-3-(propylsulfinyl)alanine, N-acetyl-S-(2-hydroxypropyl)cysteine, 1-bromo-2-hydroxypropane-O-glucuronide, N-acetyl-S-(2-oxopropyl)cysteine, and N-acetyl-3-[(2-oxopropyl)sulfinyl]alanine. These metabolites may be formed following oxidation of 1-bromopropane to 1-bromo-2-propanol and bromoacetone and following subsequent glutathione conjugation with either of these compounds. ...
PMID:16513153 Garner CE et al; Toxicol Appl Pharmacol 215 (1): 23-36 (2006)
Three metabolites of 1-bromopropane (1-BP) were measured in urine samples collected from 30 workers exposed to 1-BP at two facilities making furniture seat cushions and evaluated for use as biomarkers of exposure. The mercapturic acid metabolite, N-acetyl-S-(n-propyl)-l-cysteine (AcPrCys), 3-bromopropionic acid (3-BPA), and bromide ion levels (Br(-)) were quantitated for this evaluation. ...
PMID:22519856 Mathias PI et al; Toxicol Mech Methods 22 (7): 526-32 (2012)
Glutathione S-alkyl transferase catalyzes the conjugation of alkyl halides and nitroalkanes in which halogen or nitro group is replaced. Further metabolism of conjugates of this group to alkylmercapturic acid sulfoxides has been reported for...1-bromopropane.
Testa, B. and P. Jenner. Drug Metabolism: Chemical & Biochemical Aspects. New York: Marcel Dekker, Inc., 1976., p. 326
For more Metabolism/Metabolites (Complete) data for 1-Bromopropane (13 total), please visit the HSDB record page.
1-bromopropane is metabolized rapidly in the liver. Three mercapturic acids are produced: N-acetyl-S-propyl cysteine, N-acetyl-S-propyl cysteine-S-oxide and N-acetyl-S-(2-hydroxypropyl)cysteine. 1-bromopropoane also reacts rapidly with glutathione and can form glutathione conjugates.
Wistar male rats were exposed to 1-bromopromane (1-BP) vapor for 6 hr a day, 5 days a week, for 3 and 4 weeks (1500 ppm) and 1 day, and 4 and 12 weeks (700 ppm). ... 1-BP in blood decreased rapidly to the detection limit within 0.7 hr. On the other hand, bromide ion persisted longer in both blood and urine; the biological half-life of bromide ion was 4.7-15.0 days in blood and 5.0-7.5 days in urine. ...
PMID:12191883 Ishidao T et al; Toxicol Lett 134 (1-3): 237-43 (2002)
1-Bromopropane, either directly or via reactive metabolites, causes molecular alterations that typically are associated with carcinogenesis, including genotoxicity, oxidative stress, and glutathione depletion. These alterations, observed mainly in vitro and in toxicity studies in rodents, are relevant to possible mechanisms of human carcinogenicity and support the relevance of the cancer studies in experimental animals to human carcinogenicity.
NTP; Report on Carcinogens, Fourteenth Edition: 1-Bromopropane CAS No. 106-94-5 (2016); Available from, as of April 2, 2018: https://ntp.niehs.nih.gov/pubhealth/roc/index-1.html